A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852) Article

Thaker, PH, Salani, R, Brady, WE et al. (2017). A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852) . 28(3), 505-511. 10.1093/annonc/mdw635

Open Access

cited authors

  • Thaker, PH; Salani, R; Brady, WE; Lankes, HA; Cohn, DE; Mutch, DG; Mannel, RS; Bell-McGuinn, KM; Di Silvestro, PA; Jelovac, D; Carter, JS; Duan, W; Resnick, KE; Dizon, DS; Aghajanian, C; Fracasso, PM

sustainable development goals

authors

publication date

  • March 1, 2017

keywords

  • ABT-888
  • CANCER
  • CELL
  • CONCURRENT CHEMOTHERAPY
  • III TRIAL
  • Life Sciences & Biomedicine
  • Oncology
  • PARP inhibitors
  • PELVIC RADIATION
  • RISK
  • STAGE IVB
  • Science & Technology
  • TOPOTECAN
  • UTERINE CERVIX
  • cervical cancer
  • novel therapeutics

Digital Object Identifier (DOI)

publisher

  • ELSEVIER

start page

  • 505

end page

  • 511

volume

  • 28

issue

  • 3